drugset

drugset / Trial / NCT04587908

A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）

NCT04587908 ↗

Phase 3 Active not recruiting 104 enrolled Taiho Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of TAS-205 in patients with Duchenne muscular dystrophy

Timeline

Start: 2020-11-01
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAS-205	Unknown	—	Oral

Indications